Literature DB >> 23715906

Elevated (18)F-fluorodeoxyglucose uptake in the interventricular septum is associated with atrioventricular block in patients with suspected cardiac involvement sarcoidosis.

Osamu Manabe1, Hiroshi Ohira, Keiichiro Yoshinaga, Takahiro Sato, Alisa Klaipetch, Noriko Oyama-Manabe, Yoichi M Ito, Ichizo Tsujino, Masaharu Nishimura, Nagara Tamaki.   

Abstract

PURPOSE: Cardiac involvement in sarcoidosis is one of the leading causes of death associated with abnormalities of the conduction system. (18)F-FDG PET is useful for detecting inflammatory lesions in cardiac sarcoidosis. However, the relationship between ECG abnormalities and focal (18)F-FDG uptake has not been studied. The aim of this study was to evaluate the relationship between electrocardiogram (ECG) abnormalities and the location of elevated myocardial (18)F-FDG uptake in patients with sarcoidosis.
METHODS: Included in the study were 50 patients (56.3 ± 14.9 years old) with histologically proven sarcoidosis with suspected cardiac involvement based on ECG or echocardiography. All patients had fasted for at least 6 h and were given unfractionated heparin (50 IU/kg) intravenously to reduce the physiological (18)F-FDG uptake in the myocardium. The left ventricle (LV) wall was divided into 17 segments by visual analysis. Obvious accumulation in each segment was defined as positive.
RESULTS: Of the 50 patients, 33 showed some ECG abnormalities, including atrioventricular (AV) block in 13. Patients with abnormal ECG findings had a higher number of regions with (18)F-FDG uptake than patients without ECG abnormality (3.48 ± 2.73 vs. 1.41 ± 2.09 regions, p = 0.0051). Among ECG abnormalities, the predictor for interventricular septum wall (18)F-FDG involvement was AV block (p = 0.0025).
CONCLUSION: Patients with ECG abnormalities showed a higher number of abnormal (18)F-FDG myocardial uptake regions than patients without ECG abnormalities. In particular, focal (18)F-FDG uptake in the interventricular septum in cardiac sarcoidosis was associated with AV block. Therefore, determination of regional (18)F-FDG distribution might contribute to patient management in cardiac sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23715906     DOI: 10.1007/s00259-013-2460-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  43 in total

1.  Updated imaging guidelines for nuclear cardiology procedures, part 1.

Authors: 
Journal:  J Nucl Cardiol       Date:  2001 Jan-Feb       Impact factor: 5.952

Review 2.  Sarcoidosis.

Authors:  Michael C Iannuzzi; Benjamin A Rybicki; Alvin S Teirstein
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

3.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons.

Authors:  Andrew E Epstein; John P DiMarco; Kenneth A Ellenbogen; N A Mark Estes; Roger A Freedman; Leonard S Gettes; A Marc Gillinov; Gabriel Gregoratos; Stephen C Hammill; David L Hayes; Mark A Hlatky; L Kristin Newby; Richard L Page; Mark H Schoenfeld; Michael J Silka; Lynne Warner Stevenson; Michael O Sweeney; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Christopher E Buller; Mark A Creager; Steven M Ettinger; David P Faxon; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick A Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Lynn G Tarkington; Clyde W Yancy
Journal:  Circulation       Date:  2008-05-15       Impact factor: 29.690

4.  A dose-response study of the anticoagulant and lipolytic activities of heparin in normal subjects.

Authors:  A C Asmal; W P Leary; F Thandroyen; J Botha; S Wattrus
Journal:  Br J Clin Pharmacol       Date:  1979-05       Impact factor: 4.335

5.  Early detection of cardiac sarcoid lesions with (18)F-fluoro-2-deoxyglucose positron emission tomography.

Authors:  Hiroshi Ohira; Ichizo Tsujino; Takahiro Sato; Keiichiro Yoshinaga; Osamu Manabe; Noriko Oyama; Masaharu Nishimura
Journal:  Intern Med       Date:  2011-06-01       Impact factor: 1.271

Review 6.  ¹⁸F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis.

Authors:  Hiroshi Ohira; Ichizo Tsujino; Keiichiro Yoshinaga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-11       Impact factor: 9.236

7.  Postpartum complete atrioventricular block due to cardiac sarcoidosis: steroid therapy without permanent pacemaker.

Authors:  Kazuro Sugishita; Yuki Togashi; Akira Aizawa; Masako Asakawa; Shin-ichi Usui; Nobuhiko Ito; Tetsuo Yamaguchi; Yoshiyuki Hada; Toshiyuki Takahashi
Journal:  Int Heart J       Date:  2008-05       Impact factor: 1.862

8.  Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis.

Authors:  Ron Blankstein; Michael Osborne; Masanao Naya; Alfonso Waller; Chun K Kim; Venkatesh L Murthy; Pedram Kazemian; Raymond Y Kwong; Michifumi Tokuda; Hicham Skali; Robert Padera; Jon Hainer; William G Stevenson; Sharmila Dorbala; Marcelo F Di Carli
Journal:  J Am Coll Cardiol       Date:  2013-10-16       Impact factor: 24.094

9.  Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis.

Authors:  K J Silverman; G M Hutchins; B H Bulkley
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

10.  Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis.

Authors:  Hiroshi Ohira; Ichizo Tsujino; Shinji Ishimaru; Noriko Oyama; Toshiki Takei; Eriko Tsukamoto; Masatake Miura; Shinji Sakaue; Nagara Tamaki; Masaharu Nishimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12-15       Impact factor: 9.236

View more
  20 in total

1.  Optimizing radionuclide imaging in the assessment of cardiac sarcoidosis.

Authors:  John P Bois; Panithaya Chareonthaitawee
Journal:  J Nucl Cardiol       Date:  2015-08-13       Impact factor: 5.952

2.  Cardiac fibroma with high 18F-FDG uptake mimicking malignant tumor.

Authors:  Atsuro Masuda; Osamu Manabe; Noriko Oyama-Manabe; Masanao Naya; Masahiko Obara; Mamoru Sakakibara; Kenji Hirata; Satoshi Yamada; Tomoaki Naka; Hiroyuki Tsutsui; Nagara Tamaki
Journal:  J Nucl Cardiol       Date:  2015-12-16       Impact factor: 5.952

Review 3.  Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations.

Authors:  Shinichiro Kumita; Keiichiro Yoshinaga; Masao Miyagawa; Mitsuru Momose; Keisuke Kiso; Tokuo Kasai; Masanao Naya
Journal:  J Nucl Cardiol       Date:  2019-08       Impact factor: 5.952

4.  Opening the door to noninvasive assessment of cardiac transplant rejection: It's all in the preparation.

Authors:  Pavithra S Jayadeva; Nathan Better
Journal:  J Nucl Cardiol       Date:  2018-06-14       Impact factor: 5.952

5.  Continuing evolution in preparation protocols for 18FDG PET assessment of inflammatory or malignant myocardial disease.

Authors:  John P Bois; Panithaya Chareonthaitawee
Journal:  J Nucl Cardiol       Date:  2016-03-25       Impact factor: 5.952

6.  Pitfalls of 18F-FDG PET for evaluating myocardial viability.

Authors:  Osamu Manabe; Noriko Oyama-Manabe; Masanao Naya; Tadao Aikawa; Mamoru Sakakibara; Hiroyuki Tsutsui; Nagara Tamaki
Journal:  J Nucl Cardiol       Date:  2016-06-20       Impact factor: 5.952

Review 7.  Current status of nuclear cardiology in Japan: Ongoing efforts to improve clinical standards and to establish evidence.

Authors:  Keiichiro Yoshinaga; Nagara Tamaki
Journal:  J Nucl Cardiol       Date:  2015-04-22       Impact factor: 5.952

8.  Comparison of (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis.

Authors:  Hiroshi Ohira; David H Birnie; Elena Pena; Jordan Bernick; Brian Mc Ardle; Eugene Leung; George A Wells; Keiichiro Yoshinaga; Ichizo Tsujino; Takahiro Sato; Osamu Manabe; Noriko Oyama-Manabe; Masaharu Nishimura; Nagara Tamaki; Alexander Dick; Carole Dennie; Ran Klein; Jennifer Renaud; Robert A deKemp; Terrence D Ruddy; Benjamin J W Chow; Ross Davies; Renee Hessian; Peter Liu; Rob S B Beanlands; Pablo B Nery
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-11       Impact factor: 9.236

9.  18F-FDG-PET in Finnish patients with clinical suspicion of cardiac sarcoidosis: Female sex and history of atrioventricular block increase the prevalence of positive PET findings.

Authors:  Heikki Tuominen; Atte Haarala; Antti Tikkakoski; Pasi Korkola; Mika Kähönen; Kjell Nikus; Kalle Sipilä
Journal:  J Nucl Cardiol       Date:  2017-06-05       Impact factor: 5.952

Review 10.  Updates on the Role of Imaging in Cardiac Sarcoidosis.

Authors:  Yan Yatsynovich; Damian Valencia; Mikhail Petrov; Juan David Linares; Mufti M Rahman; Nathaniel Dittoe
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.